Jeffrey J Miceli
Affiliation: Pfizer Global Research and Development
- Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorderJeffrey J Miceli
Pfizer Global Research and Development, New London, Connecticut 06320, USA
Clin Ther 32:472-91. 2010..Antipsychotic agents have been associated with a prolonged QT interval. Data on the effects of ziprasidone and haloperidol on the QTc interval are lacking...
- Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorderJeffrey J Miceli
Pfizer Global Research and Development, New London, Connecticut, USA
Pharmacotherapy 30:127-35. 2010..To characterize the effect of oral ziprasidone and haloperidol on the corrected QT (QTc) interval under steady-state conditions. Design. Prospective, randomized, open-label, parallel-group study...
- Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteersJeffrey J Miceli
Pfizer Global Research and Development, Groton, CT, USA
J Clin Pharmacol 45:620-30. 2005..No significant effects on renal function or other laboratory values were noted. These results support the use of IM ziprasidone in treating acutely agitated patients with schizophrenia...
- A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibitionEdmund P Harrigan
Pfizer Global Research and Development, New London, CT 06320, USA
J Clin Psychopharmacol 24:62-9. 2004..The theoretical risk of cardiotoxicity associated with QTc prolongation should be balanced against the substantial clinical benefits associated with atypical antipsychotics and the likelihood of other toxicities...